Friday, March 22, 2019 12:30:36 AM
You make a very valid point to which I have alluded in previous posts.
Candidly, I believe that big P and other experts, real and so-called, think that DCVaxL works. The real question is not whether it works but how well.
As an investor, even assuming that the results are stellar at top line announcement and all endpoints are comfortably achieved with milestone/long tail home runs covering a broad spectrum of GBM cancers, i.e., M+ and MES for example or about 60% of ndGBM, would the price rise significantly and be sustainable in face of nefarious forces keeping a lid on any rise and then walking the price down again casting doubts upon commercialization challenges, dilutive financings, etc. Would investors need to wait months if not a year for reg approvals after top line announcements? How powerful are these forces? Is it a question where, as a practical matter, you just can't fight nefarious "city hall"? I must admit that I don't know the answer to that. We have seen how well these forces conspire to keep the lid on when good news issues. The data published in the JTM was excellent as were the updates at SNO. We are close to the finish line but the stock price languishes and there is not enough momentum to keep the upward spike going for long. FUD and manipulation continue rampantly and unchecked. CI darlings not even in phase III are bought out at billion dollar valuations but NWBO can't sustain itself at $300 million.
However, just imagine market reaction and what the manipulators/shorts will do if the primary/secondary endpoints are not met. The focus will be that the trial failed; that this failure is attempted to be salvaged by appeal to other criteria; and, hence approval is still highly risky and will not issue anytime soon if at all. The stock continues to languish at current levels and well below a dollar. Any reverse split to get uplifted to NASDAQ, etc. will be met by furious shorting, thus nullifying the reason for the R/S in the first place. Back to square one and rinse,repeat. Financing will be required with once again deep discounts and warrant incentives.
Thus, it is critically important for the primary and secondary endpoints to be met, not necessarily for RA approvals, although that would be helpful, for share price appreciation
and sustainability. If these endpoints are not met, investors had better plan for a very long term ROI. JMHO.
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • Oct 10, 2024 8:09 AM
FEATURED CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM